ALT241122P8000
- 0.03
- 0.000.00%
Altimmune Newsroom
Amgen (AMGN.US) released mid-term data on the weight loss therapy MariTide, showing weight loss effects comparable to Novo Nordisk.
Amgen announced on Tuesday that its experimental weight loss therapy MariTide achieved significant results in Phase 2 trials.
Altimmune to Participate at Two Upcoming Investor Conferences
White House Proposes Big Expansion of Medicare, Medicaid Coverage of Obesity Drugs
Trump Nominates Marty Makary For FDA Commissioner
Executive Reshuffles: TWO, CYBR, PFG and ALT
Altimmune Presents New Data On The Effect Of Pemvidutide On Inflammatory Lipids In Subjects With Metabolic Dysfunction-Associated Steatotic Liver Disease At The Liver Meeting 2024
Altimmune Third Quarter 2024 Earnings: Beats Expectations
Eli Lilly and Co. is startled, novo-nordisk a/s saves the day! The market prospects for weight loss drugs still tempt many players.
The weight loss drug market still has a broad prospect, with most institutions predicting that the market size will reach the trillion-dollar level by the end of this decade.
10 Health Care Stocks With Whale Alerts In Today's Session
H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $12
Altimmune Call Volume Above Normal and Directionally Bullish
Altimmune Provided Key Pipeline Updates With Q3 Report, Says B. Riley
Altimmune's Pemvidutide Progress and Expansion: A Buy Recommendation by Patrick Trucchio
Altimmune's Pemvidutide Looks Differentiated Among GLP-1s, Says H.C. Wainwright
Evercore Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $25
Altimmune (ALT) Receives a Buy From Evercore ISI
B.Riley Financial Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20
Altimmune | 10-Q: Q3 2024 Earnings Report
Tyson Foods Posts Better-Than-Expected Earnings, Joins Shopify, Sea, Buckle And Other Big Stocks Moving Higher On Tuesday
Altimmune Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results. Also, UBS Initiated Coverage on the Stock With a Buy Rating and Announced a Price Target of $26.